The news: Kimberly-Clark has agreed to buy consumer health company Kenvue for more than $40 billion.

Why it matters: The acquisition significantly expands Kimberly-Clark’s presence in the over-the-counter (OTC) consumer health market.

Kimberly-Clark’s best-known brands include Huggies, Kleenex, and Scott, while its OTC health portfolio is mostly limited to adult incontinence and feminine hygiene products. Meanwhile, Kenvue’s health brands include pain relief medications such as Tylenol and Motrin, allergy products Benadryl and Zyrtec, and skincare brands like Neutrogena.

What’s driving the acquisition: More US consumers are prioritizing health and wellness purchases—even while cutting back on other spending.

• 23% of US adults said they plan to keep spending on health and wellness despite cutting back elsewhere, making it the top non-negotiable category amid new tariffs, according to an April 2025 LoopMe survey.
• Nearly one-third of Gen Zers and millennials and up to one-quarter of older cohorts said they’re prioritizing wellness a lot more compared with last year, per a May 2025 McKinsey report. This includes spending on discretionary items such as health-monitoring devices but also essential OTC products like oral care or cold and cough medications.

An uncertain bet on beauty: Acquiring Kenvue is a gutsy move by Kimberly-Clark. While the deal would give the CPG maker instant entry into the beauty and wellness market—where margins are high and demand is increasing—it would also be saddled with reinvigorating Kenvue’s beauty and skincare brands.

• Net sales at Kenvue’s skin health and beauty segment fell 3.2% YoY in Q3, with declines in Asia-Pacific and North America only partly alleviated by growth in EMEA and Latin America. By contrast, L’Oréal’s dermatological unit grew 1.1% YoY on a reported basis during roughly the same period.
• The company has been hampered by a late start to ecommerce, which is challenging growth prospects as more beauty dollars shift from places like drugstores to online channels like Amazon.
• Kimberly-Clark will need to invest in ecommerce, as well as innovation and marketing, to turn Kenvue’s beauty business around—but its lack of category expertise, as well as the need to cut costs in the wake of an expensive acquisition, could hamper those efforts.

Other challenges: Kimberly-Clark is acquiring a company facing some operational turbulence. Kenvue fired its CEO in July after activist investors expressed concern over underperforming sales.

Kenvue is also dealing with numerous lawsuits from families who claim that Tylenol use during pregnancy caused autism in their children. A new lawsuit filed just last week by Texas Attorney General Ken Paxton alleged that parent company Johnson & Johnson and Kenvue failed to disclose evidence that acetaminophen (Tylenol's active ingredient) is dangerous to unborn children and young children. The latest legal action comes amid recent comments made by President Donald Trump and federal health officials warning pregnant women and mothers about the unproven link between Tylenol use and neurological conditions in children.

Implications for the consumer health and wellness market: Consumers’ self-reported spending on health products has not translated into recent sales growth for Kenvue. Cost-conscious shoppers may be seeking cheaper, store-brand alternatives to popular medication brands. Still, the health and wellness product category has consistently proven resilient, and the deal gives Kimberly-Clark ownership of brands long regarded as consumer staples. Kimberly-Clark will need to navigate Tylenol’s legal challenges, but scientific evidence and the lack of successful autism-related lawsuits against J&J or Kenvue are in its favor.

Implications for the beauty care market: Kimberly-Clark’s acquisition of Kenvue would create the second-largest CPG company in the world, with 10 billion-dollar brands. But the value of those brands is in flux due to shifting consumer patterns that favor less expensive private-label brands and beauty competitors like L’Oreal.

• To extract maximum value from Kenvue, Kimberly-Clark will have to take a leaf from competitor Procter & Gamble and rely on innovation and marketing to revitalize sales.
• Turning around the beauty business should be a priority, given the legal and PR challenges facing Tylenol, as well as that category’s relative resilience. We expect skincare to be the fastest-growing beauty category until 2029, making Neutrogena’s recovery both a significant opportunity and a major challenge for Kimberly-Clark.